Physician profile
Yi Teo
NPI 1205445038
$737.39
in general payments reported to CMS, 2019-2025
13 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.32 · 2022: $132 · 2023: $272 · 2024: $204 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.05 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.42 | 2022 | |
| United Therapeutics Corporation | $102.18 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.08 | 2024 | |
| Novo Nordisk INC | $64.28 | 2023 | Ozempic |
| Grifols USA, LLC | $54.69 | 2024 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $35.82 | 2023 | Ultomiris |
| Glaxosmithkline, LLC. | $29.03 | 2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $27.32 | 2021 | |
| Fresenius Kabi USA, LLC | $23.97 | 2023 | Idacio |
| Takeda Pharmaceuticals U.S.A., INC. | $23.02 | 2024 | Entyvio |
| Alcresta Therapeutics, INC. | $19.09 | 2023 | Relizorb |
| Karyopharm Therapeutics INC. | $18.44 | 2024 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Teo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.